TITLE:
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

CONDITION:
Myelodysplastic Syndrome

INTERVENTION:
CC-5013

SUMMARY:

      To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience
      erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration.

          -  Baseline mean hemoglobin < 10.0 g/dL (untransfused) and/or be transfusion dependent
             defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline.

          -  More than 30 days must have elapsed since any previous treatment for MDS, other than
             transfusion.

          -  Women must not be pregnant or lactating

          -  No use of another experimental study drug within 30 dy\ays of baseline

          -  Understand and sign written informed consent

          -  Able to adhere to study visit schedule, understand and comply with other protocol
             requirements.
      
